GLPwatch
Papers (9189)
Page 125 of 154, ranked by citation count.
- <sup>68</sup>Ga-NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication.
- Chronic Stress Alters Hippocampal Renin-Angiotensin-Aldosterone System Component Expression in an Aged Rat Model of Wolfram Syndrome.
- Study: Semaglutide Lowered Chronic Kidney Disease-Related Risks.
- Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States.
- Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi).
- Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus.
- Oral semaglutide (Rybelsus) for type 2 diabetes.
- GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management - current evidence and future outlook.
- Different formulations of semaglutide and oxidative stress in subjects with type 2 diabetes and MASLD: an open-label, real-life study.
- Analysis on difference in gastrointestinal hormone levels of patients with the history of diabetes and concurrent nephropathy and study on the role of liraglutide.
- The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity.
- Real-world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases.
- Long-Term Clinical and Economic Effects of Switching to Once-Weekly Semaglutide from Other GLP-1 RAs Among Patients with Type 2 Diabetes in China: A Modeling Projection Study.
- Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review.
- Semaglutide 2.4 mg versus Liraglutide 3 mg for the Treatment of Obesity in Greece: A Short-Term Cost-Effectiveness Analysis.
- The mechanism of liraglutide on promoting osteogenesis via macrophages polarization under the inflammatory and oxidative stress in osteoporosis.
- Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.
- Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data.
- Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective.
- Differential effects of liraglutide naltrexone/bupropion, and caloric restriction on metabolic parameters and beta-cell regeneration in type 2 diabetic rat model: role of beta arrestin 1.
- Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion.
- Effects of a new sustained-release microsphere formulation of exenatide, DA-3091, on obese and non-alcoholic fatty liver disease mice.
- Efficacy and safety of tirzepatide in subjects with type 2 diabetes and chronic kidney disease: a prospective, two-arm observational study.
- Incretin based therapeutics: connections to vascular biology and implications for potential cardiovascular disease prevention: Editorial to: "Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation" by Dai et al.
- Extending the reach of Exendin-4: new pathways in the control of body weight and glucose homeostasis.
- In brief: GI effects of GLP-1 receptor agonists.
- Diabetes: Cardiovascular benefits of semaglutide.
- [Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?]
- Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes.
- FDG PET in a Patient on a GLP-1 Agonist/Insulin Secretagogue.
- Choosing among the incretin agents and why it matters.
- Very-low calorie diet and Semaglutide: Synergy and long-term impact on type 2 diabetes management.
- The mechanism of glucagon-like peptide-1 participation in the osmotic homeostasis.
- [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
- The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.
- Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review.
- Drug updates and approvals: 2015 in review.
- Gastrointestinal adverse events of semaglutide in patients with overweight or obesity.
- A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules.
- Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.
- Using obesity management medications within the first year after laparoscopic sleeve gastrectomy may enhance weight-loss outcomes.
- Semaglutide in NASH-related cirrhosis: still a long way to go? - Authors' reply.
- Aliskiren, exendin-4, and insulin: their impact on endothelin receptor subtype(s) regulation/binding in type 1 diabetic rat hearts.
- A Remotely Delivered GLP-1RA-Supported Specialist Weight Management Program in Adults Living With Obesity: Retrospective Service Evaluation.
- Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study.
- Differentiation of Microencapsulated Neonatal Porcine Pancreatic Cell Clusters in Vitro Improves Transplant Efficacy in Type 1 Diabetes Mellitus Mice.
- The prospective record-breaking obesity drug tirzepatide raises concerns about affordability.
- More on Semaglutide in Early Type 1 Diabetes.
- A call to update anesthetic protocols: the hidden risks of semaglutide.
- Does Semaglutide Reduce Kidney Disease Events on Top of SGLT2 Inhibitors in Patients with CKD and T2D?
- GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients.
- Assessment of complex treatment influence on systemic inflammation in overweight type 2 diabetes patients.
- Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials.
- Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes.
- Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.
- Effect of Liraglutide on Intermittent Hypoxia-Induced Metabolic Dysfunction: From Bench to Bedside.
- The impact of oral semaglutide on glycemic control and weight reduction: a database analysis of dosing effects in Japanese individuals with type 2 diabetes.
- Glucose-lowering effects of semaglutide compared with dulaglutide using professional continuous glucose monitoring in outpatients with type 2 diabetes mellitus: a pilot study.
- Enhanced Transdermal Delivery of Liraglutide for Sustained Obesity Management.
- Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety.